Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exendin-(9-39) in Congenital Hyperinsulinism
NCT00571324Phase 2Completed
- Start
- Aug 2007
- Primary completion
- Dec 2014
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of exendin 9-39 in congenital hyperinsulinism (HI) (2 arms). Primary endpoint: Mean Blood Glucose Area Under the Curve (AUC 0-6h). Started Aug 2007; status: completed.
02
Drugs
exendin 9-39
03
Conditions
congenital hyperinsulinism (HI)
Beyond the preview
Go deeper on NCT00571324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00571324.